HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M Takahashi Selected Research

Multiple Endocrine Neoplasia Type 2b (MEN 3)

4/2014The involvement of reactive oxygen species derived from NADPH oxidase-1 activation on the constitutive tyrosine auto-phosphorylation of RET proteins.
9/2008Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
3/2001Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins.
2/2000A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.
1/2000Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M Takahashi Research Topics

Disease

63Neoplasms (Cancer)
01/2021 - 01/2000
18Carcinogenesis
07/2011 - 01/2000
13Neoplasm Metastasis (Metastasis)
01/2021 - 09/2000
13Stomach Neoplasms (Stomach Cancer)
06/2009 - 03/2000
12Lung Neoplasms (Lung Cancer)
11/2017 - 03/2000
12Infections
01/2007 - 01/2000
11Breast Neoplasms (Breast Cancer)
01/2021 - 01/2000
11Inflammation (Inflammations)
02/2016 - 02/2000
10Leukemia
07/2016 - 04/2000
10Multiple Endocrine Neoplasia Type 2a (MEN 2)
04/2014 - 01/2000
9Carcinoma (Carcinomatosis)
09/2008 - 01/2000
9Coronary Artery Disease (Coronary Atherosclerosis)
03/2007 - 03/2000
9Atherosclerosis
12/2004 - 05/2000
9Obesity
12/2001 - 01/2000
8Lymphoma (Lymphomas)
03/2017 - 10/2000
8Pain (Aches)
11/2012 - 01/2000
8Adenocarcinoma
03/2009 - 06/2000
7Insulin Resistance
06/2015 - 07/2000
7Adenoma (Adenomas)
02/2014 - 02/2000
7Fibrosis (Cirrhosis)
05/2012 - 02/2000
7Colonic Neoplasms (Colon Cancer)
03/2009 - 05/2000
7Body Weight (Weight, Body)
11/2001 - 04/2000
7Ovarian Neoplasms (Ovarian Cancer)
09/2001 - 01/2000
6Hemorrhage
01/2022 - 05/2000
6Hypoxia (Hypoxemia)
12/2021 - 12/2000
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2017 - 04/2000
6Necrosis
05/2014 - 03/2000
6Renal Cell Carcinoma (Grawitz Tumor)
01/2011 - 02/2000
6Ischemia
12/2001 - 01/2000
6Alzheimer Disease (Alzheimer's Disease)
11/2000 - 01/2000
5Colorectal Neoplasms (Colorectal Cancer)
01/2019 - 07/2000
5Multiple Endocrine Neoplasia Type 2b (MEN 3)
04/2014 - 01/2000
5Graft vs Host Disease (Graft-Versus-Host Disease)
12/2013 - 12/2000
5Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis)
09/2008 - 02/2000
5Rheumatoid Arthritis
01/2008 - 02/2001
5Neuroblastoma
08/2007 - 08/2000
5Aberrant Crypt Foci
08/2004 - 01/2000
4Hepatocellular Carcinoma (Hepatoma)
12/2021 - 12/2000
4Bone Resorption
04/2011 - 01/2000
4Pathologic Constriction (Stenosis)
01/2008 - 01/2000
4Leukocytosis (Pleocytosis)
05/2002 - 06/2000
4Hip Fractures (Intertrochanteric Fractures)
08/2001 - 04/2000
3Hepatitis
04/2021 - 12/2001
3Thrombosis (Thrombus)
04/2018 - 12/2005

Drug/Important Bio-Agent (IBA)

30Proteins (Proteins, Gene)FDA Link
06/2021 - 01/2000
16DNA (Deoxyribonucleic Acid)IBA
07/2016 - 01/2000
14CytokinesIBA
11/2014 - 04/2000
12Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2009 - 01/2000
11Peptides (Polypeptides)IBA
02/2012 - 01/2000
9Cisplatin (Platino)FDA LinkGeneric
01/2013 - 04/2000
9EnzymesIBA
11/2007 - 01/2000
8AntibodiesIBA
12/2005 - 02/2000
8Messenger RNA (mRNA)IBA
08/2004 - 07/2000
7Tyrosine (L-Tyrosine)FDA Link
04/2014 - 01/2000
7Codon (Codons)IBA
07/2001 - 05/2000
6Indicators and Reagents (Reagents)IBA
03/2022 - 09/2000
6Pharmaceutical PreparationsIBA
06/2021 - 01/2001
6Biological ProductsIBA
07/2016 - 01/2000
6Phosphotransferases (Kinase)IBA
04/2011 - 01/2000
6AdiponectinIBA
11/2001 - 06/2000
5Fluorouracil (Carac)FDA LinkGeneric
01/2019 - 01/2001
5ErbB Receptors (EGF Receptor)IBA
11/2017 - 02/2001
5Insulin (Novolin)FDA Link
06/2015 - 09/2001
5Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
04/2014 - 01/2000
5Docetaxel (Taxotere)FDA Link
06/2010 - 01/2000
5Nerve Growth Factors (Neurotrophins)IBA
03/2009 - 05/2000
5Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA
03/2009 - 09/2000
5VaccinesIBA
04/2004 - 04/2000
5OsteocalcinIBA
08/2001 - 01/2000
5Formaldehyde (Formol)FDA Link
05/2001 - 06/2000
4Hemoglobins (Hemoglobin)IBA
01/2022 - 06/2000
4Tyrosine Kinase InhibitorsIBA
11/2017 - 08/2008
4Biomarkers (Surrogate Marker)IBA
11/2014 - 04/2000
4Reactive Oxygen Species (Oxygen Radicals)IBA
04/2014 - 07/2001
4FibrinIBA
01/2011 - 07/2000
4Interleukin-10 (Interleukin 10)IBA
06/2009 - 12/2000
4Glucose (Dextrose)FDA LinkGeneric
12/2007 - 01/2000
4RNA (Ribonucleic Acid)IBA
01/2007 - 10/2001
4AzoxymethaneIBA
08/2004 - 01/2000
4AntigensIBA
04/2004 - 02/2000
4Therapeutic UsesIBA
02/2004 - 10/2000
4IronIBA
12/2001 - 07/2000
4Morphine (MS Contin)FDA LinkGeneric
12/2001 - 09/2000
4Contrast MediaIBA
11/2001 - 09/2000
4Paclitaxel (Taxol)FDA LinkGeneric
09/2001 - 04/2000
4Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
08/2001 - 11/2000
4beta CateninIBA
07/2001 - 06/2000
4Telomerase (Telomerase Reverse Transcriptase)IBA
06/2001 - 01/2000
4Amyloid (Amyloid Fibrils)IBA
05/2001 - 01/2000
3Epidermal Growth Factor (EGF)IBA
01/2021 - 02/2015
3Doxorubicin (Adriamycin)FDA LinkGeneric
09/2018 - 07/2002
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
09/2018 - 06/2010
3Anti-Bacterial Agents (Antibiotics)IBA
04/2018 - 05/2001

Therapy/Procedure

38Therapeutics
01/2022 - 01/2000
29Drug Therapy (Chemotherapy)
12/2021 - 01/2000
8Radiotherapy
01/2013 - 01/2000
6Renal Dialysis (Hemodialysis)
03/2005 - 08/2000
5Hematopoietic Stem Cell Transplantation
08/2011 - 12/2000
5Lymph Node Excision (Lymph Node Dissection)
01/2010 - 03/2000
4Immunotherapy
01/2006 - 06/2001